Fuente: https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-una-nueva-opcion-de-tratamiento-con-buprenorfina-para-el-trastorno-por-consumo-de

Para publicación inmediata: 24 de mayo del 2023

Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó la inyección subcutánea (para uso por debajo de la piel) de Brixadi (buprenorfina) de liberación prolongada para tratar el trastorno por consumo de opioides (OUD, por sus siglas en inglés) de moderado a grave. Brixadi está disponible en dos formulaciones, una inyección...

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder

For Immediate Release: May 23, 2023

Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine...

http://www.nationalacademies.org/hmd/Reports/2019/medications-for-opioid-use-disorder-save-lives.aspx?fbclid=IwAR2BzVfXVROhnI28ZD7giOBT5VNprOqjfiriL-Jv6_S9daG1_922Y4LOh4s

Medications for opioid use disorder (OUD) save lives. Yet most people with OUD in the United States receive no treatment at all, and only a fraction of those who do receive medications for OUD. With support from the National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration, the National Academies of Sciences, Engineering, and Medicine convened an expert committee to examine the...